Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 47 entries
Sorted by: Best Match Show Resources per page
Detecting divertor damage during steady state operation of Wendelstein 7-X from thermographic measurements.

The Review of scientific instruments

Rodatos A, Greuner H, Jakubowski MW, Boscary J, Wurden GA, Pedersen TS, König R.
PMID: 26931848
Rev Sci Instrum. 2016 Feb;87(2):023506. doi: 10.1063/1.4941717.

Wendelstein 7-X (W7-X) aims to demonstrate the reactor capability of the stellarator concept, by creating plasmas with pulse lengths of up to 30 min at a heating power of up to 10 MW. The divertor plasma facing components will...

Cite
Rodatos A, Greuner H, Jakubowski MW, et al. Detecting divertor damage during steady state operation of Wendelstein 7-X from thermographic measurements. Rev Sci Instrum. 2016;87(2):023506doi: 10.1063/1.4941717.
Rodatos, A., Greuner, H., Jakubowski, M. W., Boscary, J., Wurden, G. A., Pedersen, T. S., & König, R. (2016). Detecting divertor damage during steady state operation of Wendelstein 7-X from thermographic measurements. The Review of scientific instruments, 87(2), 023506. https://doi.org/10.1063/1.4941717
Rodatos, A, et al. "Detecting divertor damage during steady state operation of Wendelstein 7-X from thermographic measurements." The Review of scientific instruments vol. 87,2 (2016): 023506. doi: https://doi.org/10.1063/1.4941717
Rodatos A, Greuner H, Jakubowski MW, Boscary J, Wurden GA, Pedersen TS, König R. Detecting divertor damage during steady state operation of Wendelstein 7-X from thermographic measurements. Rev Sci Instrum. 2016 Feb;87(2):023506. doi: 10.1063/1.4941717. PMID: 26931848.
Copy Download .nbib Format: NLM
FLT3 inhibitors: clinical potential in acute myeloid leukemia.

OncoTargets and therapy

Hospital MA, Green AS, Maciel TT, Moura IC, Leung AY, Bouscary D, Tamburini J.
PMID: 28223820
Onco Targets Ther. 2017 Feb 03;10:607-615. doi: 10.2147/OTT.S103790. eCollection 2017.

Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy that is cured in as few as 15%-40% of cases. Tremendous improvements in AML prognostication arose from a comprehensive analysis of leukemia cell genomes. Among normal karyotype AML cases, mutations...

Cite
Hospital MA, Green AS, Maciel TT, et al. FLT3 inhibitors: clinical potential in acute myeloid leukemia. Onco Targets Ther. 2017;10:607-615doi: 10.2147/OTT.S103790.
Hospital, M. A., Green, A. S., Maciel, T. T., Moura, I. C., Leung, A. Y., Bouscary, D., & Tamburini, J. (2017). FLT3 inhibitors: clinical potential in acute myeloid leukemia. OncoTargets and therapy, 10607-615. https://doi.org/10.2147/OTT.S103790
Hospital, Marie-Anne, et al. "FLT3 inhibitors: clinical potential in acute myeloid leukemia." OncoTargets and therapy vol. 10 (2017): 607-615. doi: https://doi.org/10.2147/OTT.S103790
Hospital MA, Green AS, Maciel TT, Moura IC, Leung AY, Bouscary D, Tamburini J. FLT3 inhibitors: clinical potential in acute myeloid leukemia. Onco Targets Ther. 2017 Feb 03;10:607-615. doi: 10.2147/OTT.S103790. eCollection 2017. PMID: 28223820; PMCID: PMC5304990.
Copy Download .nbib Format: NLM
Histopathological profiles of nephropathies in senegal.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia

Abdou N, Boucar D, El Hadj Fary KA, Mouhamadou M, Abdoulaye L, Mamadou Mourtala KA, Saidou D, Abdoulaye P, Therese MD.
PMID: 18209451
Saudi J Kidney Dis Transpl. 2003 Apr-Jun;14(2):212-4.

Few data from West Africa are available on the prevalence of the different kidney diseases. One hundred fifteen patients underwent renal biopsy in the nephrology department in Dakar from 1993 to 1998. Nephrotic syndrome was the main indication of...

Cite
Abdou N, Boucar D, El Hadj Fary KA, et al. Histopathological profiles of nephropathies in senegal. Saudi J Kidney Dis Transpl. 2003;14(2):212-4
Abdou, N., Boucar, D., El Hadj Fary, K. A., Mouhamadou, M., Abdoulaye, L., Mamadou Mourtala, K. A., Saidou, D., Abdoulaye, P., & Therese, M. D. (2003). Histopathological profiles of nephropathies in senegal. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 14(2), 212-4.
Abdou, Niang, et al. "Histopathological profiles of nephropathies in senegal." Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia vol. 14,2 (2003): 212-4.
Abdou N, Boucar D, El Hadj Fary KA, Mouhamadou M, Abdoulaye L, Mamadou Mourtala KA, Saidou D, Abdoulaye P, Therese MD. Histopathological profiles of nephropathies in senegal. Saudi J Kidney Dis Transpl. 2003 Apr-Jun;14(2):212-4. PMID: 18209451.
Copy Download .nbib Format: NLM
Malignant histiocytosis with a Langerhans cell subtype: A report on the diagnostic and therapeutic challenge.

Blood cells, molecules & diseases

Kime A, Bréal C, Cottereau AS, Friedrich C, Decroocq J, Kaltenbach S, Lupo A, Copin MC, Pasmant E, Deschamps P, Emile JF, Bouscary D, Burroni B.
PMID: 34751149
Blood Cells Mol Dis. 2021 Dec;92:102623. doi: 10.1016/j.bcmd.2021.102623. Epub 2021 Oct 28.

No abstract available.

Cite
Kime A, Bréal C, Cottereau AS, et al. Malignant histiocytosis with a Langerhans cell subtype: A report on the diagnostic and therapeutic challenge. Blood Cells Mol Dis. 2021;92:102623doi: 10.1016/j.bcmd.2021.102623.
Kime, A., Bréal, C., Cottereau, A. S., Friedrich, C., Decroocq, J., Kaltenbach, S., Lupo, A., Copin, M. C., Pasmant, E., Deschamps, P., Emile, J. F., Bouscary, D., & Burroni, B. (2021). Malignant histiocytosis with a Langerhans cell subtype: A report on the diagnostic and therapeutic challenge. Blood cells, molecules & diseases, 92102623. https://doi.org/10.1016/j.bcmd.2021.102623
Kime, Amel, et al. "Malignant histiocytosis with a Langerhans cell subtype: A report on the diagnostic and therapeutic challenge." Blood cells, molecules & diseases vol. 92 (2021): 102623. doi: https://doi.org/10.1016/j.bcmd.2021.102623
Kime A, Bréal C, Cottereau AS, Friedrich C, Decroocq J, Kaltenbach S, Lupo A, Copin MC, Pasmant E, Deschamps P, Emile JF, Bouscary D, Burroni B. Malignant histiocytosis with a Langerhans cell subtype: A report on the diagnostic and therapeutic challenge. Blood Cells Mol Dis. 2021 Dec;92:102623. doi: 10.1016/j.bcmd.2021.102623. Epub 2021 Oct 28. PMID: 34751149.
Copy Download .nbib Format: NLM
Management of patients with multiple myeloma in the era of COVID-19 pandemic: how hospital at home changes our medical practice.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Fouquet G, Franchi P, Mittaine-Marzac B, Laporte N, Ihaddadene H, Decroocq J, Breal C, Bouscary D, Ammar F, Zogo A, Burgun S, Zerbit J, Willems L, Deau-Fischer B, Vignon M.
PMID: 34056680
Support Care Cancer. 2021 May 31; doi: 10.1007/s00520-021-06297-4. Epub 2021 May 31.

No abstract available.

Cite
Fouquet G, Franchi P, Mittaine-Marzac B, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: how hospital at home changes our medical practice. Support Care Cancer. 2021;doi: 10.1007/s00520-021-06297-4.
Fouquet, G., Franchi, P., Mittaine-Marzac, B., Laporte, N., Ihaddadene, H., Decroocq, J., Breal, C., Bouscary, D., Ammar, F., Zogo, A., Burgun, S., Zerbit, J., Willems, L., Deau-Fischer, B., & Vignon, M. (2021). Management of patients with multiple myeloma in the era of COVID-19 pandemic: how hospital at home changes our medical practice. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, . https://doi.org/10.1007/s00520-021-06297-4
Fouquet, G, et al. "Management of patients with multiple myeloma in the era of COVID-19 pandemic: how hospital at home changes our medical practice." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer vol. (2021). doi: https://doi.org/10.1007/s00520-021-06297-4
Fouquet G, Franchi P, Mittaine-Marzac B, Laporte N, Ihaddadene H, Decroocq J, Breal C, Bouscary D, Ammar F, Zogo A, Burgun S, Zerbit J, Willems L, Deau-Fischer B, Vignon M. Management of patients with multiple myeloma in the era of COVID-19 pandemic: how hospital at home changes our medical practice. Support Care Cancer. 2021 May 31; doi: 10.1007/s00520-021-06297-4. Epub 2021 May 31. PMID: 34056680; PMCID: PMC8164914.
Copy Download .nbib Format: NLM
Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia.

Frontiers in oncology

Chapuis N, Poulain L, Birsen R, Tamburini J, Bouscary D.
PMID: 31192118
Front Oncol. 2019 May 22;9:405. doi: 10.3389/fonc.2019.00405. eCollection 2019.

Metabolic reprogramming is a common cancer cell phenotype as it sustains growth and proliferation. Targeting metabolic activities offers a wide range of therapeutic possibilities which are applicable to acute myeloid leukemia (AML). Indeed, in addition to the IDH1/2-mutated AML...

Cite
Chapuis N, Poulain L, Birsen R, et al. Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia. Front Oncol. 2019;9:405doi: 10.3389/fonc.2019.00405.
Chapuis, N., Poulain, L., Birsen, R., Tamburini, J., & Bouscary, D. (2019). Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia. Frontiers in oncology, 9405. https://doi.org/10.3389/fonc.2019.00405
Chapuis, Nicolas, et al. "Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia." Frontiers in oncology vol. 9 (2019): 405. doi: https://doi.org/10.3389/fonc.2019.00405
Chapuis N, Poulain L, Birsen R, Tamburini J, Bouscary D. Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia. Front Oncol. 2019 May 22;9:405. doi: 10.3389/fonc.2019.00405. eCollection 2019. PMID: 31192118; PMCID: PMC6540604.
Copy Download .nbib Format: NLM
Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia.

Oncogenesis

Meunier G, Birsen R, Cazelles C, Belhadj M, Cantero-Aguilar L, Kosmider O, Fontenay M, Azar N, Mayeux P, Chapuis N, Tamburini J, Bouscary D.
PMID: 33093450
Oncogenesis. 2020 Oct 22;9(10):94. doi: 10.1038/s41389-020-00278-8.

Acute myeloid leukemia (AML) is an aggressive disease with a poor prognosis. Vacuolar protein sorting 34 (VPS34) is a member of the phosphatidylinositol-3-kinase lipid kinase family that controls the canonical autophagy pathway and vesicular trafficking. Using a recently developed...

Cite
Meunier G, Birsen R, Cazelles C, et al. Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia. Oncogenesis. 2020;9(10):94doi: 10.1038/s41389-020-00278-8.
Meunier, G., Birsen, R., Cazelles, C., Belhadj, M., Cantero-Aguilar, L., Kosmider, O., Fontenay, M., Azar, N., Mayeux, P., Chapuis, N., Tamburini, J., & Bouscary, D. (2020). Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia. Oncogenesis, 9(10), 94. https://doi.org/10.1038/s41389-020-00278-8
Meunier, Godelieve, et al. "Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia." Oncogenesis vol. 9,10 (2020): 94. doi: https://doi.org/10.1038/s41389-020-00278-8
Meunier G, Birsen R, Cazelles C, Belhadj M, Cantero-Aguilar L, Kosmider O, Fontenay M, Azar N, Mayeux P, Chapuis N, Tamburini J, Bouscary D. Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia. Oncogenesis. 2020 Oct 22;9(10):94. doi: 10.1038/s41389-020-00278-8. PMID: 33093450; PMCID: PMC7581748.
Copy Download .nbib Format: NLM
Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.

Molecular metabolism

Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P.
PMID: 34863941
Mol Metab. 2021 Dec 01;55:101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01.

OBJECTIVE: Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective cure for chronic myeloid leukemia (CML) patients and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, evidence demonstrating that TKI are unable...

Cite
Trinh A, Khamari R, Fovez Q, et al. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Mol Metab. 2021;55:101410doi: 10.1016/j.molmet.2021.101410.
Trinh, A., Khamari, R., Fovez, Q., Mahon, F. X., Turcq, B., Bouscary, D., Maboudou, P., Joncquel, M., Coiteux, V., Germain, N., Laine, W., Dekiouk, S., Jean-Pierre, S., Maguer-Satta, V., Ghesquiere, B., Idziorek, T., Quesnel, B., Kluza, J., & Marchetti, P. (2021). Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Molecular metabolism, 55101410. https://doi.org/10.1016/j.molmet.2021.101410
Trinh, Anne, et al. "Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells." Molecular metabolism vol. 55 (2021): 101410. doi: https://doi.org/10.1016/j.molmet.2021.101410
Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells. Mol Metab. 2021 Dec 01;55:101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01. PMID: 34863941; PMCID: PMC8732793.
Copy Download .nbib Format: NLM
ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS.

Molecular metabolism

Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P.
PMID: 34863941
Mol Metab. 2021 Dec 01;101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01.

Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective treatment for chronic myeloid leukemia (CML) and discontinuation of TKI therapy is now being proposed to patients with deep molecular responses. However, evidence demonstrating that TKI are unable to...

Cite
Trinh A, Khamari R, Fovez Q, et al. ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. Mol Metab. 2021;101410doi: 10.1016/j.molmet.2021.101410.
Trinh, A., Khamari, R., Fovez, Q., Mahon, F. X., Turcq, B., Bouscary, D., Maboudou, P., Joncquel, M., Coiteux, V., Germain, N., Laine, W., Dekiouk, S., Jean-Pierre, S., Maguer-Satta, V., Ghesquiere, B., Idziorek, T., Quesnel, B., Kluza, J., & Marchetti, P. (2021). ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. Molecular metabolism, 101410. https://doi.org/10.1016/j.molmet.2021.101410
Trinh, Anne, et al. "ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS." Molecular metabolism vol. (2021): 101410. doi: https://doi.org/10.1016/j.molmet.2021.101410
Trinh A, Khamari R, Fovez Q, Mahon FX, Turcq B, Bouscary D, Maboudou P, Joncquel M, Coiteux V, Germain N, Laine W, Dekiouk S, Jean-Pierre S, Maguer-Satta V, Ghesquiere B, Idziorek T, Quesnel B, Kluza J, Marchetti P. ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. Mol Metab. 2021 Dec 01;101410. doi: 10.1016/j.molmet.2021.101410. Epub 2021 Dec 01. PMID: 34863941.
Copy Download .nbib Format: NLM
The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma.

European journal of haematology

Grignano E, Laurent J, Deau B, Burroni B, Bouscary D, Kirova YM.
PMID: 29660176
Eur J Haematol. 2018 Apr 16; doi: 10.1111/ejh.13080. Epub 2018 Apr 16.

OBJECTIVE: Many salvage therapies have been proposed for relapsed/refractory (R/R) diffuse large B-cell lymphomas or for consolidation in the case of suboptimal response. Radiotherapy (RT) is one modality of salvage therapy, but its place is currently not well defined.METHOD:...

Cite
Grignano E, Laurent J, Deau B, et al. The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma. Eur J Haematol. 2018;doi: 10.1111/ejh.13080.
Grignano, E., Laurent, J., Deau, B., Burroni, B., Bouscary, D., & Kirova, Y. M. (2018). The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma. European journal of haematology, . https://doi.org/10.1111/ejh.13080
Grignano, Eric, et al. "The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma." European journal of haematology vol. (2018). doi: https://doi.org/10.1111/ejh.13080
Grignano E, Laurent J, Deau B, Burroni B, Bouscary D, Kirova YM. The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma. Eur J Haematol. 2018 Apr 16; doi: 10.1111/ejh.13080. Epub 2018 Apr 16. PMID: 29660176.
Copy Download .nbib Format: NLM
Rational for targeting the hedgehog signalling pathway in acute myeloid leukemia with FLT3 mutation.

Annals of translational medicine

Bouscary D.
PMID: 27868021
Ann Transl Med. 2016 Oct;4:S53. doi: 10.21037/atm.2016.10.29.

No abstract available.

Cite
Bouscary D. Rational for targeting the hedgehog signalling pathway in acute myeloid leukemia with FLT3 mutation. Ann Transl Med. 2016;4:S53doi: 10.21037/atm.2016.10.29.
Bouscary, D. (2016). Rational for targeting the hedgehog signalling pathway in acute myeloid leukemia with FLT3 mutation. Annals of translational medicine, 4S53. https://doi.org/10.21037/atm.2016.10.29
Bouscary, Didier. "Rational for targeting the hedgehog signalling pathway in acute myeloid leukemia with FLT3 mutation." Annals of translational medicine vol. 4 (2016): S53. doi: https://doi.org/10.21037/atm.2016.10.29
Bouscary D. Rational for targeting the hedgehog signalling pathway in acute myeloid leukemia with FLT3 mutation. Ann Transl Med. 2016 Oct;4:S53. doi: 10.21037/atm.2016.10.29. PMID: 27868021; PMCID: PMC5104592.
Copy Download .nbib Format: NLM
Elevated thrombopoietin serum concentrations in myelodysplasias.

Platelets

Lopez I, Guerci A, Bouscary D, Lacombe C, Botella A, Melle J, Dreyfus F, Fontenay-Roupie M.
PMID: 16793751
Platelets. 1998;9(5):287-90. doi: 10.1080/09537109876519.

Thrombopoietin (TPO) serum levels were quantified in patients with myelodysplastic syndromes using an ELISA test for TPO. We found that TPO levels were significantly elevated in the whole group of patients as compared with normal healthy donors (521.9 75.3...

Cite
Lopez I, Guerci A, Bouscary D, et al. Elevated thrombopoietin serum concentrations in myelodysplasias. Platelets. 1998;9(5):287-90doi: 10.1080/09537109876519.
Lopez, I., Guerci, A., Bouscary, D., Lacombe, C., Botella, A., Melle, J., Dreyfus, F., & Fontenay-Roupie, M. (1998). Elevated thrombopoietin serum concentrations in myelodysplasias. Platelets, 9(5), 287-90. https://doi.org/10.1080/09537109876519
Lopez, I, et al. "Elevated thrombopoietin serum concentrations in myelodysplasias." Platelets vol. 9,5 (1998): 287-90. doi: https://doi.org/10.1080/09537109876519
Lopez I, Guerci A, Bouscary D, Lacombe C, Botella A, Melle J, Dreyfus F, Fontenay-Roupie M. Elevated thrombopoietin serum concentrations in myelodysplasias. Platelets. 1998;9(5):287-90. doi: 10.1080/09537109876519. PMID: 16793751.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 47 entries